To provide a method for inhibiting or preventing growth of cancer cells.
A VEGF-E (vascular endothelial growth factor-E) antagonist which is a new polypeptide related to VEGF (vascular endothelial growth factor) and bone morphogenetic protein 1 is administered in combination with a second agent. Furthermore, the second agent is a chemotherapeutic agent, a growth inhibitory agent, a cytotoxic agent, an angiostatic agent, an agent used in radiation therapy, an anti-VEGF antibody, an FGF antagonist, a PDGF antagonist, or an antibody that binds to an ErbB2, an EGFR, an ErbB3, an ErbB4 or a VEGF receptor. In addition, the chemotherapeutic agent, the growth inhibitory agent, the cytotoxic agent, the angiostatic agent, the agent used in the radiation therapy, the anti-VEGF antibody, the FGF antagonist, the PDGF antagonist, or the antibody that binds to the ErbB2, the EGFR, the ErbB3, the ErbB4 or the VEGF receptor is administered as a third therapeutic agent.
SOPHIA S KUO
JPH08502514A | 1996-03-19 |
WO1996030046A1 | 1996-10-03 |
Kobayashi Yoshinori